Human T-lymphotropic virus antibody screening of blood donors: Rates of false-positive results and evaluation of a potential donor reentry algorithm

Transfusion

Volumn 51, Issue 4, 2011, Pages 692-701

  Stramer, Susan L ^a,b,c,d   Notari Iv, Edward P ^a,b,c,d   Zou, Shimian ^a,b,c,d   Krysztof, David E ^a,b,c,d   Brodsky, Jaye P ^a,b,c,d   Tegtmeier, Gary E ^a,b,c,d   Dodd, Roger Y ^a,b,c,d  

^a AMERICAN RED CROSS   (United States)

^b HOLLAND LABORATORY   (United States)

^c Quality Analytics   (United States)

^d Division of New York Blood Center Enterprises   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN T CELL LEUKEMIA VIRUS ANTIBODY;

ALGORITHM; ANTIBODY SCREENING; ARTICLE; BLOOD DONOR; CLINICAL ASSESSMENT; CLINICAL EVALUATION; ENZYME IMMUNOASSAY; FALSE POSITIVE RESULT; FOLLOW UP; HUMAN; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; PREVALENCE; SENSITIVITY ANALYSIS; SEROLOGY;

ALGORITHMS; ANTIBODIES, VIRAL; BLOOD DONORS; DONOR SELECTION; FALSE POSITIVE REACTIONS; FEMALE; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; HUMANS; IMMUNOENZYME TECHNIQUES; MALE;

EID: 79954622475     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2010.02903.x     Document Type: Article

References (26)

1. Stramer SL, Foster GA, Dodd RY,. Effectiveness of human T-lymphotropic virus (HTLV) recipient tracing (lookback) and the current HTLV-I and -II confirmatory algorithm, 1999 to 2004. Transfusion 2006; 46: 703-7.
2. Centers for Disease Control and Prevention (CDC). False-positive serologic tests for human T-cell lymphotropic virus type I among blood donors following influenza vaccination, 1992. MMWR 1993; 42: 173-5.
3. Lairmore MD, Franchini G,. Human T-cell leukemia virus types 1 and 2. In:, Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, Roizman B, editors. Fields virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007. p. 2071-105.
4. Fiebig EW, Murphy EL, Busch MP,. Human immunodeficiency virus, human T-cell lymphotropic viruses, and other retroviruses. In:, Hillyer CD, Silberstein LE, Ness PM, Anderson KC, Roush KS, editors. Blood banking and transfusion medicine: basic principles and practice. Philadelphia, PA: Churchill Livingstone; 2009. p. 447-64.
5. Murphy EL, Wang B, Sacher RA, Fridey J, Smith JW, Nass CC, Newman B, Ownby HE, Garratty G, Hutching ST, Schreiber GB,. Respiratory and urinary tract infections, arthritis, and asthma associated with HTLV-I and HTLV-II infection. Emerg Infect Dis 2004; 10: 109-16. (Pubitemid 38040701)
6. Stramer SL, Dillender MJ, Pendy LM, Holzer TJ,. False positive EIA reactivity in multiple blood bank screening assays is due to non-specific binding of IgM [Abstract no. S111]. Transfusion 1992; 32 (Suppl): 30S.
7. Centers for Disease Control and Prevention (CDC) and the U.S.P.H.S. Working Group. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann Intern Med 1993; 118: 448-54.
8. Food and Drug Administration (FDA). Donor screening for antibodies to HTLV-II. FDA guidance for industry, August 1997. [cited 2010 Apr 5]. Available from: URL
9. AABB. Dual enzyme immuno assay (EIA) approach for deferral and notification of anti-HTLV-I/II EIA reactive donors. AABB Association Bulletin #99-9, September 1999.
10. Dodd RY, Notari EP, 4th, Stramer SL,. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42: 975-9.
11. SAS JMP. Version 4, Cary, NC: SAS Institute; 2000.
12. Laperche S, Worms B, Pillonel J,. European Network of Transfusion Medicine Societies; Steering Committee. Blood safety strategies for human T-cell lymphotropic virus in Europe. Vox Sang 2009; 96: 104-10.
13. Manns A, Wilks RJ, Murphy EL, Haynes G, Figueroa JP, Barnett M, Hanchard B, Blattner WA,. A prospective study of transmission by transfusion of HTLV-I and risk factors associated with seroconversion. Int J Cancer 1992; 51: 886-91.
14. Schreiber GB, Murphy EL, Horton JA, Wright DJ, Garfein R, Chien HC, Nass CC,. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 263-71.
15. Murphy EL, Watanabe K, Nass CC, Ownby H, Williams A, Nemo G,. Evidence among blood donors for a 30-year-old epidemic of human T lymphotropic virus type II infection in the United States. J Infect Dis 1999; 180: 1777-83.
16. Kiely P, Thomas B, Kebede M,. Long-term serologic follow-up of blood donors with biologic false reactivity on an anti-human T-cell lymphotropic virus types I and II chemiluminescent immunoassay and implications for donor management. Transfusion 2008; 48: 1833-41.
17. Pancake BA, Zucker-Franklin D,. HTLV tax and mycosis fungoides. N Engl J Med 1993; 329: 580.
18. Busch MP, Murphy E, Nemo G,. More on HTLV tax and mycosis fungoides. N Engl J Med 1993; 329: 2035.
19. Busch MP, Laycock M, Kleinman SH, Wages JW Jr, Calabro M, Kaplan JE, Khabbaz RF, Hollingsworth CG,. Accuracy of supplementary serologic testing for human T-lymphotropic virus types I and II in US blood donors. Retrovirus Epidemiology Donor Study. Blood 1994; 83: 1143-8. (Pubitemid 24058567)
20. Dezzutti CS, Guenthner PC, Daniel S, Utz U, Cabrera T, Marshall JH, Bianco C, Lal RB, Cowan EP,. Detection of human T-lymphotropic virus (HTLV) tax sequences in New York city blood donors seronegative for HTLV types 1 and 2. Clin Diagn Lab Immunol 2003; 10: 715-17. (Pubitemid 36890462)
21. Vrielink H, Zaaijer HL, Cuypers HT, van der Poel CL, Woerdeman M, Lelie PN, Winkel C, Reesink HW,. Evaluation of a new HTLV-I/II polymerase chain reaction. Vox Sang 1997; 72: 144-7. (Pubitemid 27187369)
22. Liu H, Shah M, Stramer SL, Chen W, Weiblen BJ, Murphy EL,. Sensitivity and specificity of human T-lymphotropic virus (HTLV) types I and II polymerase chain reaction and several serologic assays in screening a population with a high prevalence of HTLV-II. Transfusion 1999; 39: 1185-93.
23. Thorstensson R, Albert J, Andersson S,. Strategies for diagnosis of HTLV-I and -II. Transfusion 2002; 42: 780-91.
24. Andrade RG, Ribeiro MA, Namen-Lopes MS, Silva SM, Basques FV, Ribas JG, Carneiro-Proietti AB, Martins ML,. Evaluation of the use of real-time PCR for human T cell lymphotropic virus 1 and 2 as a confirmatory test in screening for blood donors. Rev Soc Bras Med Trop 2010; 43: 111-15.
25. Sullivan MT, Williams AE, Fang CT, Grandinetti T, Poiesz BJ, Ehrlich GD,. Transmission of human T-lymphotropic virus types I and II by blood transfusion. A retrospective study of recipients of blood components (1983 through 1988). The American Red Cross HTLV-I/II Collaborative Study Group. Arch Intern Med 1991; 151: 2043-8.
26. Kleinman S, Swanson P, Allain JP, Lee H,. Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion 1993; 33: 14-18. (Pubitemid 23040323)